Skip to main content

Building a leading microbiome company in oncology

We are a clinical-stage microbiome therapeutics company aiming to
improve survival in cancer.

See News

Corporate profile

We are a clinical-stage microbiome therapeutics company aiming to restore and modulate patient-microbiome symbiosis to improve survival in cancer. To do so, we are developing a novel class of microbiome drug candidates: Microbiome Ecosystem Therapies (MET). MET are high-diversity, high-richness, indication-specific products aiming to leverage the full functional diversity of a microbiome ecosystem. Our MET drug development platform leverages gutPrint®, our proprietary AI-based computational biology and our proprietary cGMP manufacturing capacities to deliver innovative new drugs for the treatment of graft-vs-host-disease , the prevention of complications of HSCT for patients with liquid tumors and the improvement of response to immune checkpoint inhibitors in solid tumors. Our team combines expertise ranging from microbiology to data science to oncology and benefits from the commitment of world-leading scientists.

Press Releases

Press Releases

MaaT Pharma Announces Combined General Meeting on May 31, 2022 and the Availability of the Preparatory Documents

MaaT Pharma Announces Combined General Meeting on May 31, 2022 and the Availability of the…
Press Releases
MaaT Pharma Announces Resignation of an Independent Board Member
Press Releases
MaaT Pharma Reports Cash and Revenues for first quarter 2022
Press Releases
INRAE and MaaT Pharma Build on the Success of their Long-Standing Partnership with the Entry of Drug-Candidate MaaT013 into Phase 3 Clinical Trial
Press Releases
MaaT Pharma Publishes its 2021 Annual Results and Provides a Business Overview

See more

Media Coverage

Media

Interview of Hervé Affagard in Journal des biotechs – Boursorama

Media
Interview of Hervé Affagard in Boursier in French
Media
Article in French – MaaT Pharma launches its Phase 2a clinical trial in melanoma
Media
Article in French – Microbiome: MaaT Pharma starts its phase III
Media
Article in French – MaaT Pharma: A good news welcomed
Media
Interview of Hervé Affagard in Pharmaceutiques in French

See more

Posters

Videos

MaaT Pharma dans les médias MaaT Pharma in the News